welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
researchers
Eugene Gerner, PhD
Researcher Director
Gastrointestinal Cancer Program
Arizona Cancer Center
Places : The University of Arizona Cancer Center
CEO, Cancer Prevention Pharmaceuticals (CPP)
Cancer Prevention Pharmaceuticals (CPP) is a company in the late stages of developing drugs and drug combinations to treat people with risk factors for cancer. Some of these people have genetic risk factors, such as defects in the adenomatous poly posits coli tumor suppressor gene which cause the familial adenomatous polyposis (FAP) syndrome. Others have sporadic risk factors, such as prior colorectal cancer or neuroblastoma with amplified copies of the MYCN oncogene. CPP is also developing companion diagnostics for its drug therapies.
expertly curated content related to this topic
- Gabriel CapelláGabriel Capellá has worked at the Catal...
- Christina Laukaitis, MD, PhDDr. Laukaitis' interest is to understan...
- Judy E. Garber, MD, MPHDr. Garber received her MD and MPH in 19...
- Claudia MerklResearch Investigator II (lab head) in t...
- Shands Hospital at the University of FloridaPatient Resource:Patient Programs...
- Brindusa Truta, MAS, MDDr. Brindusa Truta, MAS, MD is an Assist...
- Steven GallingerHead of the Hepatobiliary and pancreatic...
English
Portuguese
Spanish